In this section
@article{Neves:2015:10.1016/j.coph.2015.09.013,
author = {Neves, AL and Chilloux, J and Sarafian, MH and Rahim, MBA and Boulange, CL and Dumas, M-E},
doi = {10.1016/j.coph.2015.09.013},
journal = {Current Opinion in Pharmacology},
pages = {36--44},
title = {The microbiome and its pharmacological targets: therapeutic avenues in cardiometabolic diseases},
url = {http://dx.doi.org/10.1016/j.coph.2015.09.013},
volume = {25},
year = {2015}
}
TY - JOUR
AB - Consisting of trillions of non-pathogenic bacteria living in a symbiotic relationship with their mammalian host, the gut microbiota has emerged in the past decades as one of the key drivers for cardiometabolic diseases (CMD). By degrading dietary substrates, the gut microbiota produces several metabolites that bind human pharmacological targets, impact subsequent signalling networks and in fine modulate host's metabolism. In this review, we revisit the pharmacological relevance of four classes of gut microbial metabolites in CMD: short-chain fatty acids (SCFA), bile acids, methylamines and indoles. Unravelling the signalling mechanisms of the microbial–mammalian metabolic axis adds one more layer of complexity to the physiopathology of CMD and opens new avenues for the development of microbiota-based pharmacological therapies.
AU - Neves,AL
AU - Chilloux,J
AU - Sarafian,MH
AU - Rahim,MBA
AU - Boulange,CL
AU - Dumas,M-E
DO - 10.1016/j.coph.2015.09.013
EP - 44
PY - 2015///
SN - 1471-4892
SP - 36
TI - The microbiome and its pharmacological targets: therapeutic avenues in cardiometabolic diseases
T2 - Current Opinion in Pharmacology
UR - http://dx.doi.org/10.1016/j.coph.2015.09.013
UR - http://hdl.handle.net/10044/1/31164
VL - 25
ER -
For any enquiries about the Microbiome Network at Imperial, please contact: